ImmunityBio Cash Flow Statement
NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
10.51+0.60 (+6.05%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ImmunityBio free cash flow
In fiscal 2025, ImmunityBio generated -$304.9 million of operating cash flow and spent $3.8 million on capital expenditures. That left free cash flow of -$308.8 million, a free-cash-flow margin of -272.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
ImmunityBio cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -351.47M | -413.64M | -583.85M | -417.32M | -349.85M | -224.19M | -160.16M | -96.23M | -96.42M | -120.81M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 15.53M | 17.55M | 18.51M | 18.26M | 14.24M | 12.74M | 14.04M | 9.55M | 5.57M | 3.61M |
| Stock-Based Compensation | 36.81M | 34.43M | 49.16M | 40.18M | 57.18M | 2.19M | 3.42M | 23.38M | 37.00M | 73.85M |
| Change in Working Capital | -46.73M | -12.10M | -518.00K | -8.56M | -5.97M | 6.78M | 7.03M | -11.43M | 1.51M | 1.18M |
| Operating Cash Flow | -304.94M | -391.24M | -366.76M | -337.51M | -274.42M | -171.72M | -152.11M | -63.38M | -48.78M | -38.59M |
| Capital Expenditures | -3.85M | -6.89M | -30.58M | -78.16M | -33.56M | -1.67M | -4.29M | -13.10M | -34.81M | -6.56M |
| Investing Cash Flow | -149.80M | -12.25M | -30.47M | 27.30M | -84.89M | -19.81M | 18.55M | 57.10M | 99.55M | -113.67M |
| Share Repurchases | — | — | — | — | 0 | 0 | -2.50M | -228.00K | -15.23M | -15.85M |
| Debt Repaid | -1.13M | 0 | 0 | — | — | — | — | — | — | — |
| Financing Cash Flow | 400.24M | 281.63M | 558.34M | 233.61M | 505.44M | 150.68M | 114.28M | -771.00K | -34.98M | -15.56M |
| Net Change in Cash | -54.48M | -121.88M | 160.82M | -76.31M | 146.19M | -40.89M | -19.30M | -7.05M | 15.79M | -167.82M |
| Free Cash Flow | -308.78M | -398.12M | -397.34M | -415.67M | -307.98M | -173.39M | -156.40M | -76.48M | -83.59M | -45.15M |
This table shows 10 annual periods of ImmunityBio's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IBRX's reporting calendar. What is a cash flow statement?